This player's pipeline should keep growth going over the long run.

AI is rewriting biotech’s commercial playbook—cutting waste, shrinking teams, and giving first‑time drugmakers a faster, ...

As Demy-Colton and EBD Group’s Biotech Showcase™ concluded its 18th year SAN FRANCISCO, CA, UNITED STATES, February 10, ...

EIR Biopharma is hoping to bring in $17.1 million from an IPO on the New York Stock Exchange that could fund development of its preclinical eye disease drug. | EIR Biopharma is hoping to bring in $17.

Makary pointed to three bottlenecks: hospital contracting; ethical reviews and approvals; and the Investigational New Drug applications process ...

Journey Medical dermatology revenue plus Emrosi near-term sales and a rare pediatric disease PRV from Zycubo approval. See ...

Unnatural Products is proving to be a natural at securing partnerships, this time linking up with Novartis in a deal that could garner up to $1.7 billion in biobucks.

Enhanced partnership brings leading investors into the review process for Startup Spotlight and Presenting Company ...

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...

Grail (GRAL) stock is plummeting after the company's three-year cancer screening trial failed to meet its main goal ...